MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Lexicon Pharmaceuticals Operating Expenses 2011-2026 | LXRX
Annual Operating Expenses Lexicon Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 101 M | - | 204 M | 149 M | 164 M | 223 M | 221 M | 119 M | 109 M | 107 M | 99.6 M | 116 M | 101 M | 101 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 223 M | 99.6 M | 140 M |
Quarterly Operating Expenses Lexicon Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -31.2 M | - | -23.1 M | - | 23.4 M | - | 23 M | 18.2 M | 20.9 M | - | 52.8 M | 73.7 M | 70.4 M | - | 69.8 M | 28.2 M | 54.9 M | - | 29.9 M | 44.1 M | 63.1 M | - | 56.5 M | 45.9 M | 60.8 M | - | 62.6 M | 57.1 M | 46.4 M | - | 34.2 M | 27.1 M | 28.3 M | - | 40.8 M | 26.8 M | 30.7 M | - | 31.5 M | 28.8 M | 25.9 M | - | 29.4 M | 25.7 M | 29.7 M | - | 26 M | 26.5 M | 29.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.7 M | -31.2 M | 35.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
43.6 M | $ 35.13 | 1.97 % | $ 945 M | USA |
|
Forte Biosciences
FBRX
|
70.7 M | $ 21.7 | 6.84 % | $ 281 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.14 | -0.67 % | $ 5.53 B |  Spain |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 91.21 | 0.94 % | $ 22 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.66 | 2.47 % | $ 442 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
281 M | $ 0.87 | 2.78 % | $ 145 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
32.2 M | $ 2.61 | -3.7 % | $ 244 M | Israel |
 |
Incyte Corporation
INCY
|
1.62 B | $ 97.69 | 0.63 % | $ 19.1 B | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 15.09 | -0.33 % | $ 216 M | USA |
 |
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Ionis Pharmaceuticals
IONS
|
752 M | $ 75.94 | 1.17 % | $ 12.2 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.4 | 2.41 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.6 | 5.61 % | $ 187 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 20.88 | 2.0 % | $ 2.66 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |